psilocybin – Page 8

Serotonin and psilocybin activate 5-HT1B receptors to suppress cortical signaling through the claustrum

mycolabadmin

Researchers found that serotonin and psilocybin (the active compound in magic mushrooms) work through the same brain mechanism to suppress certain neural signals in a brain region called the claustrum. This region controls how different parts of the cortex communicate with each other. The study shows that psilocybin directly targets serotonin 5-HT1B receptors to quiet down signals from one brain area to another, which may explain how psychedelics change cortical network activity and alter consciousness.

A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia

mycolabadmin

Australia has recently approved psilocybin and MDMA for treating severe depression and PTSD when used with professional therapy support. This paper creates a comprehensive guide outlining all the regulatory, professional, and safety considerations needed to safely deliver these treatments in clinical settings. The researchers interviewed 11 experts and reviewed existing research to identify 102 specific matters that need clear guidelines, such as what qualifications therapists need, where treatments can be delivered, how patients should be screened, and what safety measures are essential.

Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disorders

mycolabadmin

Researchers examined whether studies of three promising psychedelic drugs (esketamine, psilocybin, and MDMA) for treating mental health conditions were reporting their results fairly and completely. They found that nearly 29% of completed trials had no published results, and some studies changed which outcomes they reported on between registration and publication. This selective reporting could make these drugs appear more effective than they actually are.

Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study

mycolabadmin

Researchers investigated whether psilocybin, a compound from certain mushrooms, could be safely used to treat memory problems in older adults with mild cognitive impairment. In this early-stage study, participants received either psilocybin or a placebo while researchers used brain imaging to measure changes in synaptic connections. The preliminary results suggest psilocybin was well-tolerated with manageable side effects like dizziness, and participants were able to complete the study without serious problems.

Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology

mycolabadmin

Psilocybin, the active compound in magic mushrooms, shows promise for treating depression and other mental health conditions. This review examines how psilocybin works in the brain, particularly by affecting brain regions involved in self-reflection and emotion regulation. The authors argue that new brain recording techniques are needed to fully understand how psilocybin produces its beneficial effects, which could help improve treatments for people with severe depression.

Three New Fungi from China: A Potentially Psychoactive Psilocybe and Two Deconica Species

mycolabadmin

This research describes three new mushroom species from China: Psilocybe striata and two Deconica species. Psilocybe striata is notable for its blue bruising and potential psychoactive properties, expanding where we know psilocybin mushrooms grow. The study used both physical characteristics and genetic analysis to identify and classify these fungi, discovering that China has much greater fungal diversity than previously documented.

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

mycolabadmin

This study tested whether psilocybin (an active compound from magic mushrooms) combined with eugenol (a natural compound from cloves) could reduce brain inflammation in mice. Researchers gave mice a substance that triggers inflammation in the brain and then treated them with these compounds before or after the inflammation started. The combination treatment, especially at a 1:50 ratio of psilocybin to eugenol, significantly reduced multiple inflammatory markers in the brain, suggesting this combination could potentially be helpful for treating brain inflammation-related conditions.

DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites

mycolabadmin

Researchers examined museum specimens of magic mushrooms and found that many are mislabeled and don’t reliably contain the psychoactive compounds they should. The study shows that psilocybin breaks down unpredictably during storage, and these mushrooms contain thousands of unknown chemical compounds. These findings suggest that current regulations and our understanding of these mushrooms need significant updates.

PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity

mycolabadmin

This study is investigating whether psilocybin (an active compound in magic mushrooms) can help people with obsessive-compulsive disorder (OCD) by improving their mental flexibility and brain plasticity. Participants will receive two doses of psilocybin—a low test dose and a slightly higher therapeutic dose—four weeks apart, while receiving professional psychological support. Researchers will measure changes in cognitive abilities and brain activity to understand how psilocybin might help reduce OCD symptoms like intrusive thoughts and repetitive behaviors.

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial

mycolabadmin

This study tests whether psilocybin (a psychedelic compound) combined with intensive therapy can help treat chronic PTSD better than therapy alone. Fifteen patients with PTSD will receive one dose of psilocybin alongside 12 therapy sessions completed over a single week. Researchers will track feasibility, safety, symptom improvements, and use wearable devices to monitor physiological changes. The results will help determine whether larger trials should test this innovative combination therapy.

Research Keyword: psilocybin